Pfizer Total Current Assets decreased by 8.6% to $42.90B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 14.8%, from $50.36B to $42.90B. Over 5 years (FY 2020 to FY 2025), Total Current Assets shows an upward trend with a 4.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
A higher value relative to current liabilities indicates a strong safety margin for meeting short-term obligations.
The sum of all assets that are reasonably expected to be converted into cash or consumed within one year. This aggregate...
High-growth tech companies often maintain high current asset levels to support rapid scaling and R&D needs.
total_current_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $48.81B | $57.90B | $59.69B | $54.42B | $67.47B | $70.40B | $51.26B | $50.08B | $73.35B | $74.01B | $43.33B | $42.42B | $37.83B | $43.22B | $50.36B | $45.86B | $43.70B | $46.92B | $42.90B |
| QoQ Change | — | +18.6% | +3.1% | -8.8% | +24.0% | +4.4% | -27.2% | -2.3% | +46.5% | +0.9% | -41.5% | -2.1% | -10.8% | +14.3% | +16.5% | -8.9% | -4.7% | +7.4% | -8.6% |
| YoY Change | — | — | — | — | +38.2% | +21.6% | -14.1% | -8.0% | +8.7% | +5.1% | -15.5% | -15.3% | -48.4% | -41.6% | +16.2% | +8.1% | +15.5% | +8.6% | -14.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.